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Abstract
Considering the emergence of highly pathogenic influenza viruses and threat of worldwide pandemics, there is an urgent
need to develop broadly-protective influenza vaccines. In this study, we demonstrate the potential of T7 bacteriophage-
based nanoparticles with genetically fused ectodomain of influenza A virus M2 protein (T7-M2e) as a candidate universal flu
vaccine. Immunization of mice with non-adjuvanted T7-M2e elicited M2e-specific serum antibody responses that were
similar in magnitude to those elicited by M2e peptide administered in Freund’s adjuvant. Comparable IgG responses
directed against T7 phage capsomers were induced following vaccination with wild type T7 or T7-M2e. T7-M2e
immunization induced balanced amounts of IgG1 and IgG2a antibodies and these antibodies specifically recognized native
M2 on the surface of influenza A virus-infected mammalian cells. The frequency of IFN-c-secreting T cells induced by T7-M2e
nanoparticles was comparable to those elicited by M2e peptide emulsified in Freund’s adjuvant. Emulsification of T7-M2e
nanoparticles in Freund’s adjuvant, however, induced a significantly stronger T cell response. Furthermore, T7-M2e-
immunized mice were protected against lethal challenge with an H1N1 or an H3N2 virus, implying the induction of hetero-
subtypic immunity in our mouse model. T7-M2e-immunized mice displayed considerable weight loss and had significantly
reduced viral load in their lungs compared to controls. We conclude that display of M2e on the surface of T7 phage
nanoparticles offers an efficient and economical opportunity to induce cross-protective M2e-based immunity against
influenza A.
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Introduction
Influenza viruses are responsible for seasonal occurrences of
influenza epidemics and infrequent, unpredictable worldwide
pandemics. Each year 5–10% of the world population becomes
infected with influenza viruses, resulting in considerable public
health and economic burdens [1]. Currently licensed influenza
vaccines rely mainly on the induction of neutralizing antibodies
(Abs), which are directed mainly against the highly mutable
influenza virus hemagglutinin (HA) envelope surface glycoprotein.
Protection against influenza-associated illness by currently licensed
vaccines is well-documented for most age-group. This protection
relies on a close antigenic match between the HA present in the
vaccine strains and that of the virus strains circulating in the
population [2,3,4]. However, the antigenicity of HA changes
repeatedly over time, a process known as antigenic drift, which is
driven by escape mutants from the existing antibodies in the
population [5,6]. Therefore, the composition of seasonal influenza
vaccines has to be updated almost every each year according to the
results of global influenza surveillance performed by World Health
Organization. This annual updating process represents quite a
burden for vaccine manufacturers and in case of pandemic
outbreaks, this strategy is futile for the control of the first wave on
the pandemic. Influenza vaccines that are based on viral antigens
that are more conserved within or even between influenza A virus
subtypes, could offer a solution for this problem. One such a
candidate ‘‘universal’’ influenza A vaccine has been developed
pre-clinically as well as in phase I clinical studies [7,8] and is based
on the high sequence conservation exists in the ectodomain of the
influenza virus channel protein M2 (M2e) among various subtypes
of the virus. M2e consists of the 24 N-terminal amino acids of M2
[9]. Monoclonal antibodies against M2e have antiviral activity in
vitro [10], although this is strain-dependent, and passive admin-
istration of such monoclonal antibodies can protect laboratory
mice against influenza A virus-challenged mice [11]. Unlike most
HA-specific Abs, anti-M2e Abs fail to neutralize the virions
[10,12,13] and more likely exert their antiviral activity by binding
to M2 proteins that are expressed in relatively large amounts on
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the membrane of infected host cells [9]. Although the exact
mechanisms by which anti-M2e Abs protect against virus
challenge have not yet been determined, both Ab-dependent
cell-mediated cytotoxicity (ADCC) and complement-dependent
cytotoxicity have been demonstrated to contribute to anti-M2e
Ab-mediated immunity [14,15]. Among IgG isotypes, IgG2a and
to a lesser extent IgG2b have been shown to be the most important
mediators of ADCC in mice [16,17] and these are typically
induced by Th1 cells that express cytokines such as IFN-c upon
activation [18]. In mice, M2e-specific IgG2a (BALB/c) and IgG2c
(BL/6) offers stronger protection against influenza A virus
challenged compared to IgG1 [15,19].
M2e has a poor immunogenicity during a natural influenza A
virus infection, presumably due to its limited expression on virions
[20] and induces very low titers of M2e-specific antibodies in
humans [21]. Hence, in recent years several researchers have been
trying to improve the immunogenicity of the M2e peptide. It is
believed that antigens can be rendered more immunogenic for B
cells when presented in a highly repetitive and organized way, an
approach that allows efficient cross-linking of B cell immunoglob-
ulin receptors followed by increased signaling to B cells
[22,23,24,25]. For example, such an approach has been tested
for M2e peptide by fusing it to a branched multiple antigenic
peptide platform [26,27] or by displaying M2e on the surface of
various recombinant virus-like particles (VLPs) derived from
hepatitis B virus core antigen, Papillomavirus L1 capsid protein,
Papaya mosaic virus, phage QB as a chemical or genetic fusion
[28,29,30,31,32]. Another interesting approach to enhance M2e-
immunogenicity was by fusing M2e to the TLR5 ligand flagellin
[29].
T7 phage nanoparticles have been exploited previously for
display of peptides and B cell epitopes such as Ep15 peptide of
West Nile virus [33] and an immuno-dominant region of Hepatitis
B virus surface antigen (HBsAg) for diagnostic or vaccination
purposes [34]. In this study, we developed a universal influenza
vaccine based on T7 phage nanoparticles displaying M2e (T7-
M2e). For this, we generated a genetic fusion of M2e with the 10B
capsid protein of the T7 phage. Such phages could be easily
purified and after removal of the co-purified bacterial lipopoly-
saccharide (LPS) the immunogenicity of the T7-M2e nanoparticles
was assessed in mice. Humoral immune responses against both
M2e peptide and structural proteins of T7 carrier were induced
and M2e-specific IgG antibody isotypes (IgG1 and IgG2a) were
further characterized and quantified by peptide- and infected cell-
based ELISA. Finally, we demonstrated in vivo protection of T7-
M2e nanoparticles against a lethal infection with H1N1 or H3N2
influenza A virus in a mouse model.
Materials and Methods
Ethics Statement
All procedures used in this study were approved by the
Institutional Ethical Committee and Research Advisory Commit-
tee of Tehran University of Medical Sciences (May 21, 2011;
proposal code 240/785) based on the National Specific Ethical
Guidelines for Biomedical Research issued by Ministry of Health
and Medicinal Education (MOHME) of Iran issued in 2005.
Primer and Peptide Synthesis
All primers used in sequencing and cloning steps were
synthesized and desalted by Eurofins MWG, Germany. Peptides
corresponding to influenza A virus M2e (SSLLTEVETPIR-
NEWGCRCNGSSD) and a well-characterized Plasmodium yoelii
H-2Kd-restricted control peptide (SYVPSAEQI) [35,36] were
synthesized and HPLC purified (.98% purity) by Genscript
(USA). Two potential overlapping M2e CTL epitopes (P3–11:
LLTEVETPI ) and (P7–15: VETPIRNEW) were predicted in silico
and similarly synthesized and purified. Peptides were provided as
lyophilized preparations and reconstituted in sterile deionized
water and stored at 220uC before use.
Cloning of M2e in T7Select 415-1b Genomic Arms and
Generation of T7-M2e Phages
The oligonucleotide encoding M2e peptide with a glycine-
glycine-glycine-serine (GGGS) linker was codon optimized
according to the codon usage table of Escherichia coli strain B in
Codon Usage Database (http://www.kazusa.or.jp/codon/) using
Eurofins MWG online software, GENEius. The synthetic M2e
insert was first cloned into pCDNA3.1, which served as a template
for amplification by a high-fidelity PCR using pfu DNA
polymerase (Fermentas), pcDNA3.1-M2e template and the
flanking primers (Forward: 59-TAGCGGTTTGACTCACGG-
39) and (Reverse: 59-ATGCCTGCTATTGTCTTCC-39). The
PCR product was digested with EcoRI and HindIII restriction
enzymes and the M2e-endoding 103 bp insert was purified. The
T7Select415-1b cloning kit containing the T7415-1bEcoRI/
HindIII double-digested and dephosphorylated T7 phage genomic
arms (Novagen, Germany) was used to display M2e peptide on T7
phage head as a fusion to the C-terminus of 10B capsid protein
(Fig. 1). The T7 capsid shell contains 415 copies of 10B capsid
protein, thus M2e is displayed on the resulting T7 nanoparticles
with a high copy number. The ligation reaction was performed
with the T4 DNA Ligase (Fermentas) and overnight incubation at
16uC. Four microliters of the ligation reaction was mixed with
25 ml of T7 phage packaging extract and incubated for 2 h at
room temperature. Full-length wild type T7 phage genomic DNA
was also packaged and used as control phage nanoparticles (T7-wt)
throughout the study. The reactions were stopped by adding
270 ml of sterile Luria-Bertani (LB) broth and the packaging
efficiency was determined by titration by plaque assay using E. coli
BL21 as a host according to the technique described by Adams
[37]. The plaques were counted and the phage titers expressed as
PFU/ml.
Immunoscreening of Recombinant T7-M2e Phage
Plaques
Immunoscreening of T7 plaques was performed as described by
Jinag et al. for T4 phage with some modifications [38]. In brief, T7
bacteriophage plaques resulting from T7-M2e or T7-wt packaging
reactions were transferred to nitrocellulose membranes for 30 min
at 4uC, air-dried for 15 min and blocked with skim milk (5% in
TBS) for 1 hour. The membranes were washed once in TBS
containing 0.05% Tween-20 and incubated with 1/1000 dilution
of anti-M2e monoclonal antibody 14C2 (Abcam) in the same
buffer for 2 hours at RT. The bound antibodies were detected by
an alkaline phosphatase (AP)-conjugated goat anti-mouse IgG
(Abcam) and subsequent addition of a chromogen mixture of 5-
Bromo-4-Chloro-3 Indolylphosphate p-Toluidine salt (BCIP) and
Nitro Blue Tetrazolium Chloride (NBT). When the intensities of
phosphatase catalyzed plaque staining were judged as strong
enough, the membranes were rinsed with deionized water and
dried at room temperature. Positive M2e-dislaying plaques were
picked by aligning the membrane with plates. PCR on plaque-
derived material was performed according to manufacturers’
instruction. Briefly, a portion of the top agarose of an individual
plaque of interest was scraped and dispersed in a tube containing
100 ml of 10 mM EDTA, pH 8.0. The tube was heated for 10 min
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at 65uC and clarified by centrifugation at 14000 g for 3 min. PCR
reaction was performed on 2 ml of the clarified sample using Taq
DNA polymerase (Fermentas) and T7 specific primers (Up primer:
59-GGAGCTGTCGTATTCCAGTC-39 and Down primer: 59-
AACCCCTCAAGACCCGTTTA-39).
Large-scale Amplification and Purification of T7-M2e
Phage Nanoparticles
A volume of 1000 ml M9LB medium (Luria-Bertani broth
supplemented with 50 ml 20X M9 salts, 20 ml 20% glucose and1
ml 1 M MgSO4 per liter) was inoculated with 10 ml of a saturated
culture of BL21 and incubated overnight at 30uC to reach a final
OD600 nm= 0.8–1. The number of cells in the culture medium was
determined and bacteria were infected with the phage nanopar-
ticles at a multiplicity of infection (MOI) of 0.001. The culture was
incubated by vigorous shaking at 37uC until complete lysis of cells
was observed, which typically required 3–6 hours. To degrade
bacterial DNA and RNA released during lysis, DNase I and
RNase A (Roche, USA) were added 20 min before harvesting the
phages from the culture medium. After addition of solid NaCl
(1 M), the suspension was centrifuged for 25 min at 4000 g to
separate the bacterial debris from the T7 phage nanoparticles.
The resulting supernatant was stored overnight at 4uC after
addition of 10% polyethylene glycol (PEG 6000; Sigma). The
mixture was centrifuged for 15 min at 11000 rpm and 4uC. The
supernatant was decanted and the pellet containing the T7 phages
was resuspended in a buffer solution of 1 M NaCl, 10 mM Tris–
HCl pH 8 and 1 mM EDTA. The PEG was removed by two
consecutive centrifugations for 15 min at 10,000 rpm, followed by
extraction with an equal volume of chloroform to remove residual
PEG and bacterial debris. After centrifugation at 3000 g and 4uC
for 10 min, the upper aqueous phase containing T7 phage
nanoparticles was transferred to a new tube. The phage
nanoparticles were further purified by ultracentrifugation on a
four-step gradient of cesium chloride (CsCl) in Tris-HCl buffer
according to manufacturer’s instructions (40000 rpm, 35 min at
20uC). The band containing phage particles was isolated from the
gradient and residual CsCl was removed by three consecutive
exchanges with pyrogen-free PBS and concentrated in a centrif-
ugal ultrafiltration device (Sartorius) with 100 KDa molecular
weight cut-off (MWCO). The purified T7 nanoparticles were
sterilized using a pyrogen-free 0.2 mm pore size cellulose acetate
filter (Millipore) and quantified by plaque assay as described.
Endotoxin Removal from T7-M2e Phage Nanoparticles
The bacterial endotoxin (LPS) concentration in all T7
nanoparticle preparations was determined in triplicate using a
sensitive colorimetric Limulus Amebocyte Lysate (LAL) QCL-
1000H kit (Lonza, USA) according to the manufacturer’s
instructions. LPS was removed from T7 phage nanoparticles
based on a method for removal of endotoxin from protein
solutions by phase separation using Triton X-114 as described by
Aida et al. [39] and modified by Hashemi et al. (manuscript
submitted for publication).
SDS-PAGE and Western Blotting
SDS-PAGE was performed according to the method described
by Laemmli [40]. Briefly, purified T7-M2e and T7-wt nanopar-
ticles (as negative control) were mixed with 2x-sample buffer
[(62.5 mM Tris-HCl (pH 6.8), 25% glycerol, 2% SDS, 0.01%
bromophenol blue and 200 mM dithiothreitol (DTT)] and boiled
for 10 min. Western blotting was performed according to the
method of Towbin [41]. The protein samples were electropho-
resed on a 12% polyacrylamide gel and stained with Coomassie
brilliant blue (Fig. 2C). For Western blotting, proteins were
transferred onto nitrocellulose membranes (Sigma) using a semi-
dry blotting device (APELEX, France) for 2 h. Membranes were
blocked with 5% skim milk in TBS overnight at 4uC. Anti-M2e
monoclonal antibody 14C2 (Abcam) was added in TBS plus 0.1%
BSA at final concentration of 1 mg/ml followed by extensive
washing with TBS plus 0.05% Tween-20. Next, the membrane
was incubated with AP-conjugated goat anti-mouse IgG polyclon-
al antibody (Abcam) for 1 hr and the protein bands were
visualized by adding a mixture of BCIP/NBT (Novagen) (Fig. 2D).
Immunization of Mice
Immunogenicity studies were performed in 6–8 weeks old
female BALB/c mice (Pasteur Institute, Iran) and vaccine
Figure 1. Schematic diagram of the 10B-M2e chimeric capsid protein displayed on the T7-M2e phage nanoparticles. M2e peptide
with a GGGS linker is fused to C-terminus of 10B capsid protein after amino acid residue 348 of 10B coat protein. TAA stop codon (#) was inserted
downstream of the M2e sequence to avoid any C-terminus extension of the M2e peptide.
doi:10.1371/journal.pone.0045765.g001
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preparations were injected subcutaneously. T7 and T7-M2e phage
nanoparticles with or without Freund’s adjuvant were injected at
109 pfu per mouse. As a positive control 100 mg of the synthetic
M2e peptide adjuvanted with Freund’s adjuvant was used as a
vaccine. In addition, T7 nanoparticles mixed with 100 mg of the
free synthetic M2e peptide (T7-wt+M2e group) were administered
to assess whether multivalent display of M2e on the surface of T7
capsids is critical for eliciting an immune response against this
peptide. Separate groups of mice received PBS or Freund’s
adjuvant (CFA/IFA group) as negative controls. Mice were
primed on day 0 and boosted twice at 2-week intervals. In the
case of adjuvanted nanoparticles or M2e peptide, the antigen was
administered in CFA (Sigma) on day 0 and in IFA (Sigma) on days
14 and 28. Mice were housed in an environment with 12-h light/
dark cycles and received food and water ad libitum.
Evaluation of M2e-specific and Anti-T7 Carrier IgG
Antibodies by ELISA
Mice were bled through the retro-orbital vein 20 days after the
third immunization to determine pre-challenge IgG titers. Blood
samples were left to clot at RT for 1 h followed by at least 5 h at
4uC for contraction of clots. The sera were collected by
centrifugation for 10 min at 1200 rpm and stored at 220uC until
analysis. The titers of total IgG and isotypes (IgG1 and IgG2a) in
serum directed against the M2e peptide and T7 nanoparticles
(anti-carrier Abs) were determined by ELISA. Ninety six-well high
binding ELISA microplates (COSTAR, USA) were coated with
109 T7-wt phage nanoparticles in Tris-NaCl resuspension buffer
(PH 8) or M2e peptide (10 mg/ml) in carbonate-bicarbonate buffer
(100 mM, PH 9.6) for 1 hour at RT and then overnight at 4uC.
Plates were blocked with 5% skim milk in PBS for 1 hour at 37uC
and washed once with PBS containing 0.05% Tween-20 (PBST)
buffer. Sera were serially diluted in PBS plus 0.1% BSA and added
to wells. After incubation at 37uC for 2 h and performing washing
steps, AP-conjugated goat polyclonal anti-mouse IgG (1/20,000
dilution), anti-mouse IgG1 (1/5000 dilution) or IgG2a (1/5000
dilution) was added. A yellow color was developed after addition of
SIGMA-FAST para-nitro phenyl phosphate (pNPP) substrate in
Tris buffer which was stopped by addition of 50 ml of 3N NaOH.
Absorbance of the plates was read at 405 nm using a microplate
ELISA reader (TECAN). All serum samples from individual mice
were assessed in triplicate.
Binding Capacity of Anti-sera to M2 Expressed on
Influenza Virus-infected Cells
Immune sera were assessed for specific binding to MDCK cells
infected with PR8 virus as described previously [21]. Briefly,
MDCK cells were grown to near confluence in 96-well plates in
DMEM containing 10% FBS at 37uC and 5% CO2. The cells
were infected by 1 multiplicity of infection (MOI) of PR8 virus in
DMEM without serum or incubated with medium alone as
uninfected control. After 1 hour incubation at 37uC, DMEM
medium (without serum) was added to each well and plates were
incubated for 12 hours at 37uC. Next, plates were washed
thoroughly in cold complete medium, fixed with 10% formalin at
room temperature for 10 min, washed with PBS and blocked with
200 ml/well of 1% BSA in PBS for 1 hour. Sera from mice in each
group were pooled, two-fold diluted and added to wells in
triplicate. Serial dilutions of mice sera in PBS containing 0.1%
BSA were added to the wells and incubated for 90 min at room
temperature. After washing with PBS, HRP-conjugated goat anti-
mouse IgG (Abcam) was added and incubated for 1 hour at room
temperature followed by detection with Tetramethylbenzidine
(TMB) substrate. The same treatments were performed on non-
infected MDCK cells to determine background immune-reactivity
of the anti-sera. The reaction was stopped by adding 50 ml of 1 M
H2SO4 and OD450 nm was measured on a microplate spectropho-
tometer (TECAN).
Isolation of Spleen Cells
The day before challenge with influenza viruses (20 days after
the second booster) 5 mice from each group were sacrificed by
cervical dislocation. Spleens were aseptically removed and
splenocytes were harvested after homogenization and removal of
debris by filtration through a 70 mm nylon cell strainer (BD). Red
blood cells (RBCs) were lysed using a Tris-ammonium chloride
buffer (NH4Cl 0.16 M, Tris-HCl 0.17 M) and splenocytes were
washed several times with PBS. Finally splenocytes were
Figure 2. Plaque lift assay on T7-M2e and T7-wt plaques. Plaques developed after in vitro packaging reaction were transferred onto
nitrocellulose membranes. After incubation with 14C2 Ab followed by anti-mouse polyclonal conjugate and development by BCIP/NBT chromogen,
sharp spots were developed immediately (2–3 min) indicating accessibility and immunoreactivity of M2e peptide when displayed on the surface of
T7 nanoparticles (A). No spots are observed on T7-wt phage plaque lift (B). Following amplification and purification of T7 phage nanoparticles, capsid
proteins were separated by SDS-PAGE on 12% polyacrylamide gel (C) and 10B-M2e fusion protein (40 kDa MW) was detected by Western blotting on
nitrocellulose membrane using 14C2 anti-M2e monoclonal antibody (D). As shown, no bands were detected on the T7-wt lane indicating no reactivity
of 14C2 mAb with capsid proteins. M lane: protein marker. (E) Assessment of T7-M2e stability against various harsh conditions. There was no
significant change in the T7-M2e phage titer after incubation for 60 min at 37uC. Results are reported as PFU/ml.
doi:10.1371/journal.pone.0045765.g002
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resuspended in complete RPMI-1640 medium containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 IU/ml penicillin, 100 mg/ml streptomycin and
HEPES buffer. Cell viability was determined by trypan blue dye
(0.4% w/v) exclusion.
Measurement of M2e-specific T Cell Responses by
Interferon-c (IFN-c) ELISPOT Assay
Specific T-cell responses to M2 peptide were assessed ex vivo by a
mouse IFN-c Enzyme-linked Immunosorbent Spot (ELISPOT)
Assay kit (eBioscience). Ninety six-well Multiscreen IP Plates
(Millipore) were coated with 100 ml of assay diluent containing
anti–IFN-c monoclonal Ab and incubated overnight at 4uC. The
plates were washed and then blocked with RPMI-1640 medium
containing 10% fetal bovine serum (FBS) for 60–90 min at room
temperature. Splenocytes depleted of erythrocytes were added to
wells (300,000 cells/well in 100 ml) in triplicate and stimulated
with M2e Peptide (10 mg/ml). Furthermore, we performed an in
silico analysis of M2e peptide to predict potential H-2Kd-restricted
CTL epitopes. Two overlapping 9-mer peptides with the highest
MHC binding affinity, proteasome cleavage and TAP transport
scores were selected (P3–11: LLTEVETPI and P7–15: VETPIR-
NEW) and added to the wells in the same concentrations as full-
length M2e. The mitogen phytohemagglutinin (PHA) was added
to positive control wells at final concentration of 4 mg/ml and
Plasmodium yoelii H-2Kd peptide (as irrelevant peptide: SYVP-
SAEQI) was used as a negative control (10 mg/ml). After
incubation for 36 h at 37uC and 5% CO2, the bound IFN-c
was detected with a biotinylated monoclonal antibody. Spots were
developed on the membranes using HRP-conjugated streptavidin
and a mixture of aminoethylcarbazole (AEC) (Sigma) substrate
and H2O2 in acetate buffer and counted under a dissection
microscope (Nikon).
Amplification and Titration of Influenza Viruses
The mouse-adapted influenza A viruses used for challenge
studies were A/Puerto Rico/8/34 (PR8) and X47 virus (a
reassortant H3N2 subtype virus) [42]. Viruses were amplified by
inoculation into the allantoic cavity of 10-day-old embryonated
chicken eggs. The eggs were incubated at 35uC for 3 days and
then chilled at 4uC. The allantoic fluids were harvested and tested
for presence of haemagglutinin (HA) activity by mixing 50 ml of
supernatant with 50 m1 of a 0.5% suspension of guinea pig RBCs.
Madin-Darby Canine kidney cells (MDCK) were inoculated with
serial log10 dilutions of the clarified allantoic fluids and the 50%
tissue culture infectious dose (TCID50) was calculated after 72
hours. For challenge of mice, the viruses were quantified as 50%
mouse lethal dose (MLD50) by the Reed-Muench method.
Challenge of Mice with Influenza Viruses
Three weeks after the second booster injection, mice were
anesthetized with a mixture of 10% ketamine (100 mg/kg) and
2% xylazine (10 mg/kg) and challenged by intranasal administra-
tion of 50 ml PBS containing 4 LD50 of mouse-adapted PR8 or
X47 virus. Mortality and clinical symptoms including weight loss,
ruffled fur, hunched posture, rapid breathing, inactivity and
paralysis of posterior limb were monitored for 14 days after
challenge.
Determination of Viral Loads in Lungs
Five days after challenge, five mice from each group were
sacrificed by cervical dislocation for titration of residual lung virus.
Lungs were aseptically removed from mice, rinsed in sterile PBS
and homogenized in 2 ml ice-cold PBS containing 100 IU/ml
penicillin and 100 mg/ml streptomycin. Lung homogenates were
clarified by centrifugation for 10 min at 2400 rpm to pellet cell
debris and the supernatants stored at 220uC until assay. Semi-
confluent MDCK cells in 96-well plates were infected with serial
log10 dilutions of clarified lung samples in DMEM containing
TPCK-treated trypsin. After incubation for 72 h at 37uC in 5%
CO2, the culture supernatants were tested for the presence of
influenza virus HA activity by mixing 50 ml of supernatant with
50 ml of a 0.5% suspension of guinea pig RBCs. The virus titer for
each lung specimen was calculated by the Reed-Muench method
and expressed as the 50% tissue culture infective dose (TCID50).
The virus titers are represented by the mean 6 SD of the virus
titer per ml of the lung homogenates prepared from five mice in
each group.
Statistical Analysis
Antibody titers, body weight changes and lung residual virus
titers were compared among different groups of mice by Student’s
t test and one-way ANOVA followed by Turkey’s and Dunnett’s
post-tests. Analysis of T cell data was performed using one-way
ANOVA followed by Turkey’s test. Survival data were analyzed
by Kaplan–Meier method and log-rank test was used to analyze
differences among survival curves. Values of *p,0.05, **p,0.01,
***p,0.001 were considered statistically significant. All statistical
analyses were performed using the GraphPad Prism 5 software (La
Jolla, CA, USA).
Results
M2e is Efficiently Displayed on T7-phage Nanoparticles
A high titer of T7-M2e phage nanoparticles (1011 pfu/ml) was
obtained by infection of E. coli BL21 culture at MOI= 0.01–0.001
after a few hours of incubation (3–5 h). Display of M2e in plaques
derived from T7-M2e phages was demonstrated in a bacterio-
phage plaque lift assay using the M2e-specific monoclonal
antibody 14C2 (Fig. 2A, B). T7 phages are known to be very
stable in the environment [43]. To evaluate the stability of the
M2e-modified T7 phages, we incubated T7-wt and T7-M2e
phages in 1% SDS (a strong denaturing anionic detergent), 1%
sodium deoxycholate (DOC) and 10 mM EDTA (a strong Ca2+
and Mg2+ ion chelator, which destabilizes many protein-protein
interactions) and a combination of these agents for 1 h at 37uC.
Such incubations did not compromise the integrity of T7
nanoparticles as assessed by plaque assay (Figure 2E). These
results indicate that display of M2e peptide on all 415 monomers
of 10B capsid protein did not interfere with the assembly of T7-
M2e nanoparticles in infected bacteria. In addition, the purified
T7-M2e phages retained their infectivity following incubation in
harsh denaturing conditions, suggesting that banked T7-M2e
phages would be a reliable inoculum source to produce M2e-
vaccine [43].
T7-M2e Phage Nanoparticles Elicit a Robust Anti-M2e and
Anti-T7 Carrier IgG Antibody Response
To determine the immunogenicity of our T7-M2e based
nanoparticles, we immunized BALB/c mice via the subcutaneous
route with purified, endotoxin-free phages in the presence or
absence of Freund’s adjuvant. In the absence of adjuvant, T7-M2e
phage nanoparticles elicited a high titer of serum anti-M2e IgG
antibody response as determined by M2e peptide ELISA (Fig. 3a).
This suggests that T7 phage nanoparticles are highly immuno-
genic in mice even in the absence of additional adjuvants or
contaminating bacterial LPS. Moreover, high levels of anti-T7
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carrier IgG antibodies were induced against structural proteins of
T7 nanoparticles as measured by serum ELISA performed on
plates coated with T7-wt nanoparticles (Fig. 3b). Because we
observed a high titer of IgG Abs against both T7 nanoparticle
capsids and M2e peptide, we concluded that carrier-specific
antibodies did not suppress the development of an M2e-specific
IgG response in immunized mice. Isotypes of M2e-specific IgG in
anti-sera were characterized by ELISA using IgG1- and IgG2a-
specific secondary antibodies. As shown in figure 3, T7-M2e
nanoparticles induced a balanced amount of both IgG1 and IgG2a
antibodies in mice. Immunization in the presence of CFA/IFA
adjuvant to T7-M2e nanoparticles (T7-M2e+FA group) signifi-
cantly increased both M2e-specific and anti-T7 carrier IgG
antibodies compared to the non-adjuvanted setting (p,0.01).
Moreover, anti-M2e IgG2a antibody level was significantly higher
in mice receiving T7-M2e nanoparticles formulated in Freund’s
adjuvant compared to adjuvant-free immunization (p,0.001)
indicating the induction of a Th1-dominant immune response,
whereas no significant difference was observed in IgG1 titers. To
assess this surmised M2e-specific Th1-response, we quantified the
number of IFN-c-secreting splenocytes by ELISPOT.
Sera from mice that had been immunized with a mixture of T7-
wt nanoparticles and free M2e peptide (T7-wt+M2e group)
contained significantly lower titers of anti-M2e antibodies com-
pared to T7-M2e immunized mice, indicating the importance of
multivalent arrangement of M2e peptide on the surface of T7
nanoparticles in eliciting a strong antibody response. This finding
is in accordance with the results obtained by previous studies using
Hepatitis B core, phage Qß or Papaya mosaic virus VLPs
[22,32,44]. Control mice inoculated with wild-type T7 phage
nanoparticles (T7-wt), PBS or CFA/IFA had no detectable anti-
M2e Abs. As previously reported, M2e peptide injected with
CFA/IFA (M2e+FA group) induced high titers of M2e-specific
IgG1 and IgG2a antibodies [45,46] even though these were
significantly lower than those induced by T7-M2e emulsified in
CFA/IFA (p,0.001).
Abs Elicited by T7-M2e Nanoparticles Efficiently
Recognize Native Tetrameric M2 on Influenza Virus-
infected Cells
Considering that we used a multivalent display approach for a
linear format of the M2e peptide on the surface of icosahedral
Figure 3. Antibody responses elicited by T7-M2e nanoparticles. (A) Total IgG, IgG1 and IgG2a antibody titers against the influenza virus M2e
peptide. Results are expressed as an antibody endpoint titer, where the O.D. value is 3-fold higher than the background value obtained with a 1:50
dilution of pre-immune serum from BALB/c mice. Data represent the mean 6SD of five mice. Statistically significant differences are represented by
*p,0.05, **p,0.01, and ***p,0.001. (B) Measurement of anti-T7 nanoparticle IgG antibodies by ELISA using T7-wt-coated microplates. Each value
represents mean6 SD in each group of mice. (C) Binding capacity of antibodies in vaccinated mice sera to native M2 expressed on PR8 virus-infected
MDCK cells. Results from PBS and CFA/IFA groups are not shown as there was no significant difference compared to T7-wt group. Details are
described in Results.
doi:10.1371/journal.pone.0045765.g003
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capsids of T7 phage nanoparticles, we investigated whether the
elicited antibodies could also recognize native tetrameric M2
expressed on the surface of infected cells. To analyze such
responses, we used an MDCK cell-based whole cell ELISA. As
shown in Fig. 3c, sera from mice immunized with T7-M2e
efficiently recognized native M2 expressed by PR8 virus-infected
MDCK cells, whereas only background binding was observed with
sera derived from mice that had received T7-wt, PBS or CFA/IFA
(p,0.01). Similar to the results obtained with M2e peptide-coated
ELISA plates, sera from mice administered with an emulsion of
T7-M2e in CFA/IFA showed a higher binding to virus-infected
MDCK cells although this difference was not statistically
significant. Furthermore, antibodies from the T7-M2e+FA group
bound more strongly to PR8 infected-MDCK cells compared to
sera from mice that had been immunized with M2e peptide in
CFA/IFA.
Immunization with T7-M2e Phage Nanoparticles Induces
M2e-specific T Cell Responses
To evaluate T cell-mediated immunity to M2e peptide,
splenocytes from immunized mice were stimulated in vitro with
synthetic M2e peptide and the numbers of IFN-c-secreting cells
were determined by ELISPOT. As shown in figure 4, the mice
immunized with M2e peptide plus Freund’s adjuvant or T7-M2e
nanoparticles (with or without adjuvant) showed a significantly
higher frequency of M2e-specific IFN-c-secreting cells compared
to negative controls (T7-wt, CFA/IFA and PBS) (p,0.001) and
those receiving a mixture of T7-wt and M2e peptide (p,0.01).
Moreover, T cell responses provoked by T7-M2e nanoparticles
were significantly greater than T7-wt nanoparticles combined with
synthetic M2e peptide (p,0.01) which correlates with the higher
anti-M2e IgG titers observed in sera from T7-M2e immunized
mice (Fig. 3). Co-administration of Freund’s adjuvant with T7-
M2e nanoparticles (T7-M2e+FA group) resulted in a significantly
higher number of IFN-c-producing cells compared to adjuvant-
free immunizations or M2e peptide emulsified in Freund’s
adjuvant (p,0.001). However, splenocytes from mice receiving
M2e peptide emulsified in Freund’s adjuvant had a significantly
greater frequency of IFN-c-secreting T cells than those receiving
T7-M2e nanoparticles without adjuvant (p,0.01). The number of
spots in control mice immunized with T7-wt nanoparticles, CFA/
IFA or PBS was low and similar to those obtained after in vitro
stimulation with the irrelevant H-2kd peptide. Moreover, no
significant difference was observed between the number of IFN-c
spots from the splenocytes stimulated with the irrelevant control
peptide and the in silico predicted CTL peptides, P3–11 and P7–15
(data not shown). The latter result indicates that the T7-M2e
immunogen does not give rise to cross-presentation in our model,
or that the predicted peptides are poor CTL epitopes in the H-2kd
background.
T7-M2e Nanoparticles without Adjuvant Protect Mice
Against both H1N1 (PR8) and H3N2 (X47) Virus Challenge
Twenty one days after the last injection, mice were challenged
intranasally with two mouse-adapted subtypes of influenza A virus:
PR8 and X47. T7-M2e nanoparticles, without (T7-M2e group) or
with Freund’s adjuvant (T7-M2e+FA group) protected mice
against a lethal virus infection (Fig. 5). Immunization with
adjuvanted T7-M2e nanoparticles increased the survival rate of
mice by 34% and 17% after challenge with PR8 and X47 viruses,
respectively, compared to non-adjuvanted immunization. Also,
without adjuvant, mice experienced more severe body weight loss,
although all animals in this group eventually recovered after
challenge (Fig. 5c). It has been reported that immunization with
M2e peptide formulated in CFA/IFA induced a high anti-M2e
IgG titer and protected mice against a lethal challenge with H3N2
and H1N1 (PR8) influenza virus [45,46]. However, in our
immunization/challenge setting using a similar vaccine formula-
tion we observed only partial protection and no significant
difference in survival rate compared to mice receiving T7-M2e
nanoparticles in the absence of the adjuvant. All control mice (T7-
wt, Freund’s adjuvant and PBS groups) showed excessive weight
loss and succumbed to a lethal challenge with both viruses.
Immunization with T7-M2e Nanoparticles Significantly
Reduced Influenza Virus Load in the Lungs
Challenge with PR8 virus of mice that had been immunized
with T7-M2e nanoparticles also resulted in a significant reduction
of lung virus titers compared to T7-wt, PBS and CFA/IFA control
groups (p,0.001) as shown in figure 5. However, addition of
Freund’s adjuvant significantly enhanced the antiviral effects of
T7-M2e nanoparticles as revealed by significantly lower lung virus
titer (p,0.05). Overall, survival rates and reduction of lung virus
titers correlated well in our model. No significant reduction was
observed in virus titers of mice inoculated with a combination of
M2e peptide and T7-wt nanoparticles (T7-wt+M2e group)
compared with negative controls (Fig. 5d). Finally, to document
protection by the immunization with T7-M2e nanoparticles
against a different influenza subtype virus, six mice from each
group were challenged with X47 virus, a mouse-adapted H3N2
subtype virus. The mice inoculated with T7-M2e nanoparticles
either with or without CFA/IFA survived upon challenge with
X47 virus with a survival rate of 100% and 83%, respectively
(Fig. 5b). In contrast, all control mice died by day 10–11 after
challenge with this H3N2 virus.
Discussion
A large number of studies have focused on the use of the
conserved M2e of influenza A viruses as a candidate vaccine
antigen for development of a universal influenza vaccine [7,47].
Many researchers have been trying to overcome the naturally poor
immunogenicity of M2e peptide by coupling it to an appropriate
carrier such as VLPs, multiple branched peptides or TLR ligands
[28,29,30,32,48]. In this study, we have exploited a bacteriophage
T7-based epitope display system to generate a strong M2e-
immunogen. Physical stability and several advantageous biological
features of T7 phage nanoparticles including unique multivalency
(415 copies per particle), easy and rapid propagation in laboratory
strains of E. coli, lack of requirement of displayed peptides to be
secreted through the bacterial periplasm and remarkable stability
of T7 nanoparticles in harsh denaturing conditions [43],
encouraged us to exploit this as a platform for an M2e-based
universal flu vaccine. Generally, bacteriophage nanoparticles are
believed to have no intrinsic tropism towards eukaryotic cells and
no phage multiplication in mammalian cells has been detected
[49]. Bacteriophage-derived nanoparticles have been extensively
investigated as carriers to enhance immunogenicity of various
peptides and proteins. This has been achieved either by chemical
conjugation or genetic fusion of various epitopes of immunodo-
minant antigens to the surface of icosahedral or filamentous
capsids derived from fd [50,51,52], lambda [53,54,55] and T4
phages [56,57,58,59,60]. Oral route of administration has also
been explored with bacteriophage nanoparticles. For example, it
was shown that orally delivered foot-and-mouth disease virus
capsid protein displayed on the surface of T4 nanoparticles
conferred a 100% protection against challenge with this Picorna-
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Figure 4. M2e-specific T cell responses were measured using IFN-c ELISPOT. Splenocytes were isolated from immunized mice, pooled in
each group and assayed for IFN-c-producing cells by ELISPOT as described in Materials and Methods. (A) Data are represented as number of IFN-
positive spot forming cells (SFCs) per 106 pooled splenocytes in each group6 SD. All samples were tested in triplicate. (B) Frequency of IFN-c spots in
each group of mice.
doi:10.1371/journal.pone.0045765.g004
Figure 5. Antiviral effects of T7-M2e nanoparticles. The immunized mice were challenged by 4 LD50 of mouse-adapted PR8 (H1N1) or X47
(H3N2) virus 21 days after the second booster dose and monitored for survival and clinical symptoms (body weight loss) for 14 days. T7-M2e
nanoparticles without adjuvant significantly protected mice against a lethal infection with both PR8 (A) and X47 (B) viruses as analyzed by Log-rank
test. However, addition of CFA/IFA adjuvant resulted in 100% protection of mice. (C) Body weight was monitored for all mice for 14 days post-
challenge with PR8 virus. (D) Five days post-challenge, six mice in each group were sacrificed and residual virus titers were measured in lungs as
TCID50 per ml of each lung homogenate.
doi:10.1371/journal.pone.0045765.g005
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virus in mice [61]. T7 phage nanoparticles displaying Ep15
peptide of West Nile virus have been exploited for detection of
anti-WNV IgG in patient sera [33] and induction of antibodies by
the same nanoparticles carrying the immunodominant region of
Hepatitis B virus surface antigen (HBsAg) has been demonstrated
in rabbits [34]. In the present study, we investigated whether T7
phage nanoparticles carrying a high density (415 copies per
particle) of M2e peptide on the surface as a genetic fusion to 10B
capsid protein could induce protective immunity against a lethal
challenge with influenza viruses in mice. M2e peptide was stably
displayed on the surface of T7 nanoparticles and was accessible to
anti-M2e monoclonal antibody 14C2. To exclude innate im-
munostimulatory effects exerted by bacterial LPS, a purification
procedure was adopted from Aida et al. with some modifications.
We determined the induction of humoral as well as T cell
responses directed against M2e by these T7-M2e nanoparticles in
the presence or absence of a strong adjuvant (CFA/IFA). T7-Me
nanoparticles without any additional adjuvant successfully elicited
both IgG1/IgG2a and T cell responses in mice after three
subcutaneous immunizations. Moreover, a high level of protection
(66% and 83% survival rates) was achieved by immunization with
T7-M2e nanoparticles against lethal challenge with two different
mouse-adapted subtypes of influenza A virus (PR8 and X47
viruses). However, when T7-M2e nanoparticles were emulsified in
CFA for priming and IFA for booster injections, significantly
higher M2e-specific IgG titers especially of Th1-induced IgG2a
isotype were obtained and mice were completely protected against
challenge with both viruses. Similar results were reported by Denis
et al. where immunization of mice with M2e-modified Papaya
mosaic VLPs in the absence of adjuvant conferred only a partial
protection against challenge (50% survival), while co-administra-
tion of Alum adjuvant significantly improved the survival rate of
mice and increased the level anti-M2e IgG1 without a significant
influence on IgG2a titers [44]. In other words, Alum improved a
Th2-oriented response while CFA/IFA adjuvant in our study
greatly increased both IgG2a levels in sera and IFN-c secretion in
splenocytes upon re-stimulation with M2e peptide in vitro,
indicating a Th1-dominant response. Even in a setting where free
M2e peptide was use in combination with CFA/IFA adjuvant,
substantial protection at the level of morbidity and lung virus titers
was observed. Mice from this group had significantly higher
numbers of IFN-c secreting splenocytes in response to M2e-
peptide re-stimulation compared with T7-M2e immunized mice,
even though antibody-titers directed against M2e were compara-
ble between these two groups (compare Fig. 3A and Fig. 4A). This
finding may suggest that IFN-c production by M2e-specific T cells
is an important correlate of protection for M2e-based immunity in
the mouse model, in addition to M2e-specific humoral immunity.
An M2e-specific CD4 T cell response in the BALB/c mouse
model has been described following mucosal immunization with
M2e-VLPs in adjuvanted with CTA1-DD, a safe and effective
cholera toxin derived adjuvant [62]. Generally, mouse IgG2a
isotype restrict viral infections better than IgG1 Abs [63,64]. This
is further confirmed by the observation that isotype switching of
14C2 anti-M2e monoclonal antibody from IgG1 to IgG2a
improves its protective efficacy in vivo [65,66]. The exact
mechanism(s) by which antibodies induced by M2e vaccination
mediates protection against a lethal infection has not yet been
completely elucidated. However, NK cells and alveolar macro-
phages play a crucial role as described by Jegerlehner et al. [48]
and El Bakkouri et al. [15]. IFN-c secreted by Th1 cells promotes B
cell isotype switching to IgG2a which strongly mediates opsoniza-
tion and ADCC by binding via its Fc portion to receptors on a
variety of cell types including macrophages and NK cells
[16,17,18]. Interestingly, T7-M2e nanoparticles without adjuvant
elicited a high frequency of M2e-specific IFN-c-secreting spleno-
cytes (Fig. 4) which favored production of IgG2a, in amounts
comparable to those from mice immunized with M2e peptide
combined with CFA/IFA adjuvant (Figure 3). Furthermore, most
of the mice that had received T7-M2e nanoparticles survived upon
lethal challenge with two different subtypes of mouse-adapted
influenza viruses (PR8 and X47) indicating a desirable cross-
protectivity of the described platform. No significant difference
was observed in survival rates of T7-M2e and M2e+FA groups
demonstrating high immunogenicity of M2e peptide when
displayed densely on the surface of T7 nanoparticles (Fig. 5). By
contrast, when simply mixed with T7-wt nanoparticles, M2e
peptide only triggered a minimal response against the M2e
peptide, not strong enough to protect mice against a lethal virus
infection or clinical symptoms (body weight loss). In accordance,
Denis et al. previously reported that a mixture of PapMV VLPs
with free M2e peptide failed to induce antibodies against M2e and
to protect mice against lethal challenge [44]. Our observation
further confirms the key role of particulate delivery and
multivalent arrangement of M2e peptide on the surface of
nanoparticles in triggering a strong activation signal via cross-
linking of B cell receptors and subsequent antibody production
[22]. Direct comparison in an experimental efficacy study of the
T7-M2e nanoparticle vaccine described here with e.g. M2e-MAP,
M2e-HBcore or M2e-QBeta fusion constructs would be required
to rank the protective potential of different multivalent M2e
epitope display systems. We believe that the prime benefit of the
T7-M2e nanoparticle vaccine candidate is primarily an econom-
ical one: the technology to produce and isolate T7-based particles
requires a safe prokaryotic cell system and technically straightfor-
ward physical separations steps to obtain.
No significant increase in IgG1 isotype levels were detected in
the mice receiving T7-M2e nanoparticles compared to those
inoculated with a T7-M2e/CFA/IFA emulsion. Similarly, a
multiple antigenic peptide (MAP) platform carrying multiple
copies of M2e peptide elicited higher IgG titers when administered
with CFA/IFA than with Alum compared to adjuvant-less
administration. Also, lower virus titers were detected in lungs of
mice receiving MAP-CFA/IFA [26,27]. In contrast, only back-
ground level of antibody responses and IFN-c-positive spots were
detected in the mice receiving CFA/IFA adjuvant alone or T7-wt
nanoparticles. Quantification of residual influenza viruses in lungs
showed that when challenged with virus, the mice inoculated with
T7-M2e nanoparticles were able to effectively clear virus from
their lungs comparable to those injected with M2e peptide plus
CFA/IFA (Fig. 5d). However, addition of CFA/IFA to T7-M2e
nanoparticles conferred a superior protection against a lethal
infection with both PR8 and X47 viruses and significantly
inhibited virus propagation in lungs. These results correlated well
with M2e-specific IgG2a titers in mice sera (Fig. 3). Naturally
occurring bacteriophages are able to induce humoral immunity as
phage-neutralizing antibodies have been detected in human and
animal sera probably reflecting frequent natural contact of
humans/animals with various phage species [17,63]. So we
decided to measure anti-T7 nanoparticles IgG in sera in addition
to M2e-specific Abs. Induction of anti-M2e IgG response was not
inhibited in mice immunized three times with T7-M2e nanopar-
ticles either with or without adjuvant, because high anti-M2e IgG
titers were detected in sera despite high levels of anti-T7 carrier
IgG Abs. This phenomenon known as carrier-induced epitopic
suppression (CIES) was observed with Qb VLPs particularly if
VLPs chemically conjugated with low peptide densities were used
[67]. Furthermore, the researchers reported that the observed
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suppression could be reduced or overcome by conjugating the
peptide to the VLP at high density, by repeated injections and
increasing the dose of the vaccine. Another study by De Filette et
al. showed that vaccination with M2e-HBc VLPs can induce
protective anti-M2e antibodies even in the presence of pre-existing
anti-HBc carrier antibodies [68]. In the present study, we injected
mice three times with a relatively high dose of T7-M2e
nanoparticles (109 pfu/mouse) carrying a high copy of M2e
peptide per particle which probably inhibited the epitope
suppression by anti-T7 IgG. The data presented here suggest that
pre-existing anti-T7 phage antibodies in human population would
not interfere with the rise of anti-M2e peptide antibodies in
booster administrations or compromise the efficacy of the induced
protection. However, the proof will have to come from clinical
trials involving individuals who are positive for anti-T7 phage IgG.
In conclusion, our findings suggest that T7-phage nanoparticles
carrying M2e peptide can be considered as a promising strategy to
induce protective antibodies against multiple subtypes of influenza
A viruses. However, M2e does display sequence variation in
circulating human influenza viruses. With few exceptions, this
sequence variation is confined to the membrane proximal part of
M2e (amino acid residues 10–23). For example, there are 4 amino
acid differences between M2e as used here in T7-M2e nanopar-
ticles (Fig. 1) and A/California/04/09 virus. Such sequence
variation likely affects protection induced by an M2e-based
vaccine strategy in case of an insufficient match between M2e
and the challenge virus. It has been reported that a close match
between the M2e sequence and the challenge virus improves
protection afforded by M2e-specific antibodies compared to an
incomplete match [69,70]. Although still experimental, in the
worst-case scenario of the pandemic spread of lethal influenza
viruses, a T7 phage-based universal vaccine could be co-
administered to broaden immunogenicity of currently used
seasonal influenza vaccines as evaluated by Wu et al. using a
combination of M2e peptide and split influenza vaccine [71].
However, more pre-clinical evaluation of these nanoparticles is
required in larger animals and humans. Finally, it is important to
point out that Freund’s adjuvant is a very strong inflammatory
adjuvant, and is not licensed for human use. Freund’s adjuvant is
still regularly used in experimental studies in mice to obtain proof-
of-concept for novel influenza vaccine candidates [72]. Currently,
aluminum salts (Alum) are the only human vaccine adjuvants
licensed by the Food and Drug Administration (FDA), however in
recent years, oil in water emulsions such as MF59 and AS03 have
been licensed for adjuvanted influenza vaccines in Europe [73].
While Alum is safe, it is a mild Th2 adjuvant that can effectively
enhance IgG1 antibody responses, but it is rarely associated with
Th1 type immune responses [74]. Hence, a myriad of researches
have been conducted to develop a safe and efficacious adjuvant
capable of boosting cellular plus humoral immunity [75]. Such
adjuvants would be expected to have the potential to both intensify
the immune response and also to reduce the dose of vaccine
antigen needed per vaccination or the number of injections.
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